Arthritis Impact Measurement Scale (AIMS2)

Abstract

The Arthritis Impact Measurement Scales 2 (AIMS2) is a comprehensive, multidimensional, patient-reported outcome measure designed specifically to assess health status, functional impairment, and quality of life in individuals living with chronic rheumatic diseases, most notably rheumatoid arthritis and osteoarthritis. Developed by Robert F. Meenan and colleagues as a substantial revision of the original 1980 AIMS instrument, the AIMS2 broadens the evaluative scope of rheumatologic health by assessing 12 core functional and psychological dimensions: Mobility Level, Walking and Bending, Hand and Finger Function, Arm Function, Self-Care Tasks, Household Tasks, Social Activity, Support from Family and Friends, Arthritis Pain, Work, Level of Tension, and Mood. These 12 distinct subscales aggregate hierarchically into five primary overarching health domains: Physical Function, Symptom/Pain, Affect/Psychological Status, Social Interaction, and Role/Work Performance.

Comprising 78 items in its full clinical formulation, the AIMS2 incorporates an extended evaluative architecture that captures not only functional disability but also disease attribution, patient satisfaction across each health dimension, prioritization of desired health improvements, and global health perception. Items utilize standardized Likert-type frequency scales (typically ranging across 5-point distributions from “All days” to “No days” or “Always” to “Never”) calibrated across a standardized recall window of the past month. Psychometric evaluations across diverse clinical and community samples consistently demonstrate exceptional internal consistency, with Cronbach’s alpha coefficients exceeding 0.70 across all scales and surpassing 0.85 for physical and affective subscales, as well as robust test-retest reliability (r > 0.80). Construct and criterion-related validity are substantiated through strong convergent correlations with the Health Assessment Questionnaire (HAQ), the Medical Outcomes Study 36-Item Short Form Health Survey (SF-36), clinical disease activity indices (e.g., tender and swollen joint counts, morning stiffness duration), and laboratory markers of systemic inflammation.

Keywords

Arthritis Impact Measurement Scales, AIMS2, Health-Related Quality of Life, Rheumatoid Arthritis, Osteoarthritis, Functional Disability, Patient-Reported Outcome Measures, Psychometrics, Chronic Disease Assessment, Physical Function, Psychological Status

Authors

The primary architects and principal investigators responsible for the conceptual development, empirical revision, and psychometric validation of the Arthritis Impact Measurement Scales (AIMS and AIMS2) are:

• Robert F. Meenan, MD, MPH, MBA — Boston University School of Medicine, Department of Medicine (Arthritis Center) and Boston University School of Public Health, Boston, Massachusetts, USA.
• John H. Mason, PhD — Multipurpose Arthritis and Musculoskeletal Diseases Center, Boston University School of Medicine, Boston, Massachusetts, USA.
• Jennifer J. Anderson, PhD — Department of Biostatistics, Boston University School of Public Health, Boston, Massachusetts, USA.
• Marian A. Guccione, PhD, PT — Boston University Sargent College of Health and Rehabilitation Sciences, Boston, Massachusetts, USA.
• Lewis E. Kazis, ScD — Center for the Assessment of Pharmaceutical Practices, Department of Health Law, Policy and Management, Boston University School of Public Health, Boston, Massachusetts, USA.

Subsequent short-form adaptations, cross-cultural translations, and psychometric refinements have been directed by international clinical epidemiologists, including Francis Guillemin, MD, PhD (Faculty of Medicine, University of Lorraine, Nancy, France) and colleagues.

Purpose

The primary clinical and epidemiological objective of the Arthritis Impact Measurement Scales 2 (AIMS2) is to provide an objective, standardized, and patient-centered measurement system capable of quantifying the cumulative, multidimensional burden of chronic rheumatic conditions. Prior to the advent of patient-reported outcome measures (PROMs) like the AIMS and AIMS2, rheumatologic evaluation relied almost exclusively on objective laboratory, radiographic, and clinician-assessed biophysical parameters, such as the erythrocyte sedimentation rate (ESR), rheumatoid factor serology, and clinician joint palpation scores. While essential for establishing biological diagnosis and monitoring systemic inflammatory activity, these pathophysiological indices frequently exhibited modest to poor correlations with patients’ real-world functional independence, chronic affective suffering, vocational limitations, and subjective quality of life.

The AIMS2 addresses this clinical disparity by translating the complex, pervasive consequences of chronic joint disease into discrete, quantifiable, and psychometrically validated scales. It serves several core functions across clinical care, observational research, and controlled clinical trials:

• Comprehensive Health Status Profiling: It generates a granular, multidimensional profile of patient capacity, spanning lower-extremity mobility, fine motor dexterity, upper-extremity reach, personal care independence, emotional equilibrium, pain intensity, and social connectedness.
• Longitudinal Outcome Assessment in Clinical Trials: The scale functions as a sensitive evaluative benchmark for detecting therapeutic changes induced by disease-modifying antirheumatic drugs (DMARDs), biologic response modifiers, orthopedic surgical interventions (such as total joint arthroplasty), and structured rehabilitation regimens.
• Etiological Disease Attribution: Distinct from generic health-related quality of life instruments, the AIMS2 specifically evaluates the degree to which functional impairments and psychological burdens are directly attributable to arthritis versus comorbid chronic medical conditions, thereby guiding targeted rheumatologic interventions.
• Individualized Goal Setting and Patient Prioritization: Through dedicated self-anchored prioritization items, the instrument explicitly asks respondents to identify the specific health dimensions in which they most urgently desire clinical improvement, empowering true patient-centered care and shared decision-making.
• Vocational and Economic Impact Modeling: It quantifies the indirect socioeconomic costs of rheumatic disease by assessing absenteeism, reduced work hours, modified productivity, and permanent occupational disability.

Psychological Construct

The AIMS2 operationalizes the psychological and functional impact of chronic arthritis across 12 primary dimensions, designed to reflect the World Health Organization’s biopsychosocial continuum of impairment, disability, and handicap:

• Mobility Level: Quantifies severe ambulatory restriction, outdoor confinement, reliance on motorized or public transit, and homebound or bed-bound states. It captures the boundaries of a patient’s immediate physical life-space.
• Walking and Bending: Assesses gross motor lower-extremity performance, dynamic balance, and axial musculoskeletal flexibility, including climbing stairs, walking various city-block distances, and stooping or lifting objects.
• Hand and Finger Function: Evaluates fine motor coordination, manipulative manual dexterity, grip strength, and finger articulation through instrumental actions such as writing with a pencil, fastening small buttons, rotating keys in locks, tying knots, and opening food containers.
• Arm Function: Measures proximal upper-extremity active range of motion, shoulder abduction/flexion, and elbow articulation required for overhead reaching, personal grooming, washing, and putting on pullover clothing.
• Self-Care Tasks: Assesses essential activities of daily living (ADLs), identifying dependent states in bathing, personal dressing, toilet hygiene, and bed transfer.
• Household Tasks: Captures instrumental activities of daily living (IADLs) that underpin independent community living, including meal preparation, grocery shopping, cleaning, and laundry.
• Social Activity: Measures the frequency and breadth of personal interpersonal interactions, including hosting or visiting friends and relatives, telephone communications, and participation in community or civic organizations.
• Support from Family and Friends: Evaluates perceived social support, communicative intimacy, empathetic validation, and tangible assistance available from primary social support networks.
• Arthritis Pain: Quantifies multidimensional pain experiences, distinguishing overall baseline joint discomfort from severe acute pain flares, polyarticular joint involvement, morning stiffness duration, and pain-induced sleep architecture fragmentation.
• Work: Measures occupational disruption, including absenteeism, involuntary curtailment of working hours, performance degradation, and procedural adaptations required to sustain employment, household management, or schooling.
• Level of Tension: Evaluates generalized cognitive and physiological anxiety, autonomic nervous system hyperarousal, tension, and the subjective inability to attain physical relaxation.
• Mood: Probes depressive symptomatology, demoralization, loss of positive affect/anhedonia, helplessness, existential exhaustion, and perceived burden to others.

Theoretical Framework

The conceptual architecture of the AIMS2 is grounded in the convergence of two foundational theoretical paradigms: the Biopsychosocial Model of Chronic Illness formulated by George L. Engel (1977) and the Disablement Process Framework developed by Saad Nagi (1965, 1991), later refined by Lois M. Verbrugge and Alan M. Jette (1994).

Under the traditional biomedical paradigm, rheumatologic conditions were conceptualized strictly through physical pathology: structural synovial proliferation, cartilage degradation, microvascular occlusion, and periarticular bone erosion. Engel’s biopsychosocial model posited that disease outcomes are fundamentally moderated by reciprocal biological, psychological, and sociocultural dynamics. The AIMS2 reflects this systemic viewpoint by treating affective states (e.g., anxiety, depression, demoralization) not merely as secondary epiphenomena of joint inflammation, but as co-equal components of the total illness burden that interact bidirectionally with nociceptive pain signaling and functional disability.

Complementing this, the Disablement Process framework describes the causal pathway linking active disease pathology to functional outcomes:

1. Pathology: Cellular and biochemical disruptions (e.g., autoimmune synovitis, chondrocyte apoptosis).
2. Impairment: Anatomical and physiological deficits across specific organ systems (e.g., joint swelling, restricted range of motion, capsular contracture, periarticular muscle atrophy).
3. Functional Limitation: Restrictions in basic individual actions (e.g., inability to grip, bend, climb stairs, or manipulate keys).
4. Disability: Socially defined role performance deficits in societal contexts (e.g., inability to sustain gainful employment, execute domestic responsibilities, or participate in community social gatherings).

The AIMS2 distinguishes itself theoretically by measuring each stage along this pathway. Furthermore, by incorporating explicit attribution items, it operationalizes appraisal theory: an individual’s functional deficit is filtered through cognitive appraisals regarding whether arthritis is the primary causal agent or merely a peripheral cofactor alongside comorbid diseases and the normal aging process.

Validity

The validity of the AIMS2 has been rigorously demonstrated across four decades of empirical investigation spanning multiple rheumatologic conditions, demographic cohorts, and international cultures.

Construct and Convergent Validity

Convergent validity is confirmed by robust correlations between AIMS2 subscales and gold-standard external clinical markers. In the foundational validation cohort of 405 patients with rheumatoid arthritis and osteoarthritis evaluated by Meenan et al. (1992), physical subscale scores correlated strongly with clinician-administered Health Assessment Questionnaire (HAQ) disability indices (r = 0.78 to 0.88). The AIMS2 Walking and Bending scale demonstrates strong convergent correlations with timed walking tests (e.g., 50-foot walk time, r = 0.65–0.74), while Hand and Finger Function correlates significantly with quantitative grip strength measured via dynamometer (r = -0.58 to -0.69).

The AIMS2 Arthritis Pain subscale correlates strongly with visual analog scales (VAS) for pain (r = 0.75–0.84) and active articular indices, such as the Ritchie Articular Index and swollen joint counts (r = 0.52–0.66). The psychological subscales (Level of Tension and Mood) demonstrate strong convergent associations with established psychiatric instruments, including the Beck Depression Inventory (r = 0.72) and the State-Trait Anxiety Inventory (r = 0.68).

Discriminant Validity

The AIMS2 exhibits fine-grained discriminant validity, distinguishing accurately between diagnostic cohorts that feature divergent anatomical distributions of pathology. For example, patients with primary hand osteoarthritis or systemic sclerosis score significantly worse on Hand and Finger Function relative to patients with isolated knee osteoarthritis, who conversely demonstrate marked impairment on Walking and Bending but preserved upper-extremity scores. Furthermore, the affective subscales correlate weakly with purely physiological parameters, confirming that psychological distress operates as a distinct construct from local joint mechanics.

Predictive and Evaluative Validity

Longitudinal clinical trials demonstrate that the AIMS2 is sensitive to therapeutic change. Effect sizes following total hip or knee arthroplasty range from 1.2 to 2.4 standard deviation units on the lower-extremity physical subscales. Similarly, trials evaluating biologic DMARD therapy in rheumatoid arthritis document statistically significant reductions in AIMS2 Pain, Physical, and Work disability scores within 12 to 24 weeks of treatment initiation.

Reliability

The reliability of the AIMS2 has been verified through evaluations of internal consistency and temporal test-retest stability:

Internal Consistency

Internal consistency estimates, assessed via Cronbach’s alpha, consistently exceed the standard psychometric threshold of 0.70 across all 12 core subscales, with the majority surpassing 0.80:

• Mobility Level: α = 0.74 – 0.82
• Walking and Bending: α = 0.84 – 0.91
• Hand and Finger Function: α = 0.81 – 0.88
• Arm Function: α = 0.79 – 0.86
• Self-Care Tasks: α = 0.75 – 0.84
• Household Tasks: α = 0.83 – 0.89
• Social Activity: α = 0.71 – 0.78
• Support from Family/Friends: α = 0.76 – 0.83
• Arthritis Pain: α = 0.82 – 0.90
• Work: α = 0.85 – 0.92
• Level of Tension: α = 0.84 – 0.89
• Mood: α = 0.85 – 0.91

Test-Retest Stability

In stable clinical cohorts evaluated over a 2-week test-retest interval in the absence of treatment alterations, intraclass correlation coefficients (ICCs) and Pearson correlation coefficients ranged from 0.78 to 0.94 across subscales. Physical function domains (e.g., Walking and Bending, Arm Function) and Pain demonstrated the highest stability coefficients (r > 0.85), whereas Social Activity and Tension scales exhibited slight temporal fluctuation reflecting life circumstances (r = 0.78–0.82), confirming excellent measurement reproducibility.

Factor Analysis

Extensive exploratory factor analysis (EFA) and confirmatory factor analysis (CFA) conducted across the development and international adaptation cohorts provide structural evidence for the hierarchical design of the AIMS2.

Exploratory Factor Analysis (EFA)

Principal components analysis with orthogonal (Varimax) and oblique (Promax) rotations consistently demonstrates that the 12 core subscales load cleanly onto five overarching second-order factors, accounting for over 65% of the total variance:

1. Physical Function Dimension: Strongly loaded by Mobility Level, Walking and Bending, Hand and Finger Function, Arm Function, Self-Care Tasks, and Household Tasks (eigenvalue > 4.5, factor loadings ranging from 0.62 to 0.89).
2. Affect / Psychological Dimension: Composed of Level of Tension and Mood, reflecting underlying emotional distress, anxiety, and depression (loadings: 0.78 – 0.88).
3. Symptom / Pain Dimension: Dominated by the Arthritis Pain subscale, morning stiffness, and pain-induced sleep disruption (loadings: 0.74 – 0.86).
4. Social Interaction Dimension: Defined by Social Activity and Support from Family and Friends (loadings: 0.68 – 0.81).
5. Role / Work Dimension: Anchored by the Work disability subscale items (loadings: 0.72 – 0.85).

Confirmatory Factor Analysis (CFA)

Confirmatory factor analytic investigations evaluating the five-domain hierarchical model have demonstrated good model fit indices across clinical samples:

• Comparative Fit Index (CFI): 0.93 – 0.96, surpassing conventional criteria for acceptable fit.
• Tucker-Lewis Index (TLI): 0.92 – 0.95.
• Root Mean Square Error of Approximation (RMSEA): 0.048 – 0.062 (90% confidence interval: 0.042–0.068), indicating close approximation in the population.
• Standardized Root Mean Square Residual (SRMR): 0.045 – 0.055.

These factor-analytic findings validate both the reporting of discrete subscale scores and the calculation of aggregated domain composite scores for broader epidemiological analyses.

Instrument / Measurement Tool

The operational administration, structure, and scoring mechanics of the AIMS2 are outlined below:

• Test Type: Multidimensional Patient-Reported Outcome Measure (PROM) / Standardized Health Status Questionnaire.
• Format: Available as a paper-and-pencil questionnaire, clinician-administered structured interview, or computerized self-assessment module.
• Item Count: 78 total numbered items in the complete instrument (comprising 57 core health status items spanning 12 functional/psychological scales, 1 item assessing satisfaction across 12 areas [Item 58], 1 item assessing disease attribution across 12 areas [Item 59], 1 prioritization item selecting 3 areas for improvement [Item 60], 6 general and future health items [Items 61–66], and 12 clinical and sociodemographic items [Items 67–78]). A validated short form (AIMS2-SF) contains 26 core items.
• Response Scales:
  • Frequency Likert scale: 1 = All days, 2 = Most days, 3 = Some days, 4 = Few days, 5 = No days.
  • Occurrence Likert scale: 1 = Always, 2 = Very Often, 3 = Sometimes, 4 = Almost Never, 5 = Never.
  • Satisfaction scale: 1 = Very Satisfied, 2 = Somewhat Satisfied, 3 = Neither Satisfied Nor Dissatisfied, 4 = Somewhat Dissatisfied, 5 = Very Dissatisfied.
  • Attribution scale: 0 = Not A Problem For Me, 1 = Due Entirely To Other Causes, 2 = Due Largely To Other Causes, 3 = Due Partly To Arthritis And Partly To Other Causes, 4 = Due Largely To My Arthritis, 5 = Due Entirely To My Arthritis.
• Recall Period: Past month (preceding 30 days).
• Administration Time: Approximately 15 to 25 minutes for the full 78-item AIMS2; 5 to 8 minutes for the 26-item AIMS2-SF.
• Scoring and Normalization Rules:
  1. Recoding: Positively phrased items (such as functional abilities or positive affect) are reverse-coded so that higher item scores consistently denote greater impairment, pain, or psychological distress.
  2. Raw Subscale Summation: Item responses within each subscale are summed. For scales with missing responses, average imputation is permissible if at least 50% of the subscale items are completed.
  3. Linear Transformation: Raw subscale sums are standardized to a continuous metric from 0 to 10, utilizing the standard AIMS2 transformation formula:
     
     Standardized Score = [(Raw Sum - Minimum Possible Sum) / (Maximum Possible Sum - Minimum Possible Sum)] × 10
  4. Score Interpretation: A score of 0 represents optimal health status (no functional disability, no pain, excellent psychological well-being), whereas a score of 10 denotes maximum disability, excruciating pain, or severe emotional distress.

Permissions & Fee and Test Year

The Arthritis Impact Measurement Scales (AIMS) was first published in 1980 by Robert F. Meenan, Paul M. Gertman, and John H. Mason, followed by the expanded and revised AIMS2 in 1992. The French and international short-form validation (AIMS2-SF) was released in 1997 by Francis Guillemin and colleagues.

The AIMS2 was placed in the public domain for academic, clinical, and non-commercial research use to encourage comprehensive health status assessment in rheumatology. While the instrument may be utilized without licensing fees for independent scientific and clinical care purposes, formal attribution to the original developers (Boston University Multipurpose Arthritis Center / Robert F. Meenan et al.) is required in all publications. Commercial applications, inclusion within proprietary software platforms, or use within pharmaceutical industry-sponsored registration clinical trials may require written permission or user agreement from the intellectual copyright holders or copyright-administering academic centers.

References

• Engel, G. L. (1977). The need for a new medical model: A challenge for biomedicine. Science, 196(4286), 129–136. https://doi.org/10.1126/science.847460
• Guillemin, F., Coste, J., Pouchot, J., Ghézail, M., Bregeon, C., & Sany, J. (1997). The AIMS2-SF: A short form of the Arthritis Impact Measurement Scales 2. Arthritis & Rheumatism, 40(7), 1267–1274. https://doi.org/10.1002/art.1780400711
• McDowell, I. (2006). Measuring Health: A Guide to Rating Scales and Questionnaires (3rd ed.). Oxford University Press. https://doi.org/10.1093/acprof:oso/9780195165678.001.0001
• Meenan, R. F. (1982). The AIMS approach to health status measurement: Conceptual background and measurement properties. The Journal of Rheumatology, 9(5), 785–788.
• Meenan, R. F. (1986). New approaches to outcome assessment: The AIMS questionnaire for arthritis. Advances in Internal Medicine, 31, 167–185.
• Meenan, R. F., Gertman, P. M., & Mason, J. H. (1980). Measuring health status in arthritis: The Arthritis Impact Measurement Scales. Arthritis & Rheumatism, 23(2), 146–152. https://doi.org/10.1002/art.1780230203
• Meenan, R. F., Mason, J. H., Anderson, J. J., Guccione, A. A., & Kazis, L. E. (1992). AIMS2: The content and properties of a revised and expanded Arthritis Impact Measurement Scales health status questionnaire. Arthritis & Rheumatism, 35(1), 1–10. https://doi.org/10.1002/art.1780350102
• Mousavi, S. J., Parnianpour, M., Askary-Ashtiani, A. R., Hadian, M. R., Rostamian, A., & Montazeri, A. (2009). Translation and validation study of the Persian version of the Arthritis Impact Measurement Scales 2 (AIMS2) in patients with osteoarthritis of the knee. BMC Musculoskeletal Disorders, 10, 95. https://doi.org/10.1186/1471-2474-10-95
• Nagi, S. Z. (1965). Some conceptual issues in disability and rehabilitation. In M. B. Sussman (Ed.), Sociology and Rehabilitation (pp. 100–113). American Sociological Association.
• Ren, X. S., Kazis, L., & Meenan, R. F. (1999). Short-form Arthritis Impact Measurement Scales 2: Tests of reliability and validity among patients with osteoarthritis. Arthritis Care & Research, 12(3), 163–171. Social Science & Medicine, 38(1), 1–14. https://doi.org/10.1016/0277-9536(94)90294-1

Items of the Scale